Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2014 Mar;15(3):297-304. doi: 10.1016/S1470-2045(14)70007-5. Epub 2014 Jan 31.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

Author information

  • 1Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • 2Biostatistics and Epidemiology, GlaxoSmithKline, Munich, Germany.
  • 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • 4Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy-Istituto Nazionale Tumori Fondazione "G Pascale", Napoli, Italy.
  • 5Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • 6Gustave Roussy Cancer Campus, Paris-Sud University Grand Paris, Villejuif, France.
  • 7Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, University Hospital Kiel, Kiel, Germany.
  • 8Westmead Hospital and Melanoma Institute Australia, University of Sydney, NSW, Australia.
  • 9Skin Cancer Program University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • 10Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia.
  • 11Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK.
  • 12Department of Internal Medicine 5-Hematology/Oncology, University of Erlangen, Erlangen, Germany.
  • 13Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, VIC, Australia.
  • 14Beverly Hills Cancer Center, Beverly Hills, CA, USA.
  • 15Academic Unit of Oncology, University of Nottingham, Nottingham, UK.
  • 16Dermatology and INSERM Unit 981 Gustave Roussy Cancer Campus and Paris-Sud University Grand Paris, Villejuif, France.
  • 17Department of Dermatology, University Hospital Essen, Essen, Germany. Electronic address: dirk.schadendorf@uk-essen.de.

Abstract

BACKGROUND:

Recent phase 3 trials have shown an overall survival benefit in metastatic melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded as a reliable surrogate for overall survival through a meta-analysis of randomised trials.

METHODS:

We systematically reviewed randomised trials comparing treatment regimens in metastatic melanoma that included dacarbazine as the control arm, and which reported both PFS and overall survival with a standard hazard ratio (HR). We correlated HRs for overall survival and PFS, weighted by sample size or by precision of the HR estimate, assuming fixed and random effects. We did sensitivity analyses according to presence of crossover, trial size, and dacarbazine dose.

FINDINGS:

After screening 1649 reports and meeting abstracts published before Sept 8, 2013, we identified 12 eligible randomised trials that enrolled 4416 patients with metastatic melanoma. Irrespective of weighting strategy, we noted a strong correlation between the treatment effects for PFS and overall survival, which seemed independent of treatment type. Pearson correlation coefficients were 0·71 (95% CI 0·29-0·90) with a random-effects assumption, 0·85 (0·59-0·95) with a fixed-effects assumption, and 0·89 (0·68-0·97) with sample-size weighting. For nine trials without crossover, the correlation coefficient was 0·96 (0·81-0·99), which decreased to 0·93 (0·74-0·98) when two additional trials with less than 50% crossover were included. Inclusion of mature follow-up data after at least 50% crossover (in vemurafenib and dabrafenib phase 3 trials) weakened the PFS to overall survival correlation (0·55, 0·03-0·84). Inclusion of trials with no or little crossover with the random-effects assumption yielded a conservative statement of the PFS to overall survival correlation of 0·85 (0·51-0·96).

INTERPRETATION:

PFS can be regarded as a robust surrogate for overall survival in dacarbazine-controlled randomised trials of metastatic melanoma; we postulate that this association will hold as treatment standards evolve and are adopted as the control arm in future trials.

FUNDING:

None.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PMID:
24485879
[PubMed - indexed for MEDLINE]
PMCID:
PMC4443445
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk